Literature DB >> 24484991

LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy.

Akio Oishi1, Noriko Miyamoto1, Michiko Mandai1, Shigeru Honda2, Toshiyuki Matsuoka3, Hideyasu Oh3, Mihori Kita3, Tomoko Nagai4, Nobuhiro Bessho5, Mamoru Uenishi5, Yasuo Kurimoto1, Akira Negi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24484991     DOI： 10.1016/j.ophtha.2013.12.037

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  24 in total

1.  Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Yu Kawashima; Akio Oishi; Akitaka Tsujikawa; Kenji Yamashiro; Masahiro Miyake; Naoko Ueda-Arakawa; Munemitsu Yoshikawa; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-13       Impact factor: 3.117

2.  One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.

Authors:  Mio Hosokawa; Yuki Morizane; Masayuki Hirano; Shuhei Kimura; Fumiaki Kumase; Yusuke Shiode; Shinichiro Doi; Shinji Toshima; Mika Hosogi; Atsushi Fujiwara; Toshiharu Mitsuhashi; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2016-12-07       Impact factor: 2.447

3.  Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.

Authors:  Jae Hyung Lee; Won Ki Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-03       Impact factor: 3.117

4.  Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and aflibercept.

Authors:  Maria Vadalà; Massimo Castellucci; Giulia Guarrasi; Giovanni Cillino; Vincenza Maria Elena Bonfiglio; Alessandra Casuccio; Salvatore Cillino
Journal:  Int Ophthalmol       Date:  2022-01-16       Impact factor: 2.031

5.  Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.

Authors:  Siyin Liu; Ramandeep Chhabra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-09       Impact factor: 3.535

6.  One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study.

Authors:  San-Ni Chen; Cheng-Kuo Cheng; Ling Yeung; Jiann-Torng Chen; Wei-Chun Chan; Jorn-Hon Liu; Shwu-Jiuan Sheu; Wen-Chuan Wu; Chi-Chun Lai
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

Review 7.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

Review 8.  Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.

Authors:  Aniruddha Agarwal; William R Rhoades; Mostafa Hanout; Mohamed Kamel Soliman; Salman Sarwar; Mohammad Ali Sadiq; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2015-06-05

9.  Polypoidal Choroidal Vasculopathy.

Authors:  Joon-Bom Kim; Rajinder S Nirwan; Ajay E Kuriyan
Journal:  Curr Ophthalmol Rep       Date:  2017-04-21

10.  EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.

Authors:  Colin S Tan; Wei Kiong Ngo; Louis W Lim; Nikolle W Tan; Tock H Lim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-03       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.